Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Crushing Defeat or Sign of Hope? Analyst, KOL Give Mixed Views for CheckMate-227
July 31, 2019
- Astellas Secures Q1 Growth as Xtandi, Betanis Offset LOE Impact
July 31, 2019
- Eisai Halts Epilepsy Drug Studies after Death in Japan PI
July 31, 2019
- Pfizer Japan Seeks to Expand Bosulif Label into 1st-Line CML
July 31, 2019
- Otsuka Ups Half-Year Outlook on Bullish Jynarque
July 31, 2019
- Xtandi Filed for Hormone-Sensitive Prostate Cancer in Japan
July 31, 2019
- Over 1,000 GSK Staffers Worked from Home amid Govt’s Telework Campaign
July 30, 2019
- NEC Snaps Up Norway’s Bioinformatics Firm
July 30, 2019
- Sumitomo Dainippon Ekes Out Quarterly Growth as North America Sales Offset Japan Dip
July 30, 2019
- Shionogi’s Q1 Sales Sag 10.5% after Hefty Xofluza Milestone Gain
July 30, 2019
- Mitsubishi Tanabe’s Sales Fall 6.9% as Gilenya Snafu Takes Toll
July 30, 2019
- Lonsurf Gets EU Nod for Gastric Cancer: Taiho
July 30, 2019
- Nesp Biosame to Hit Japan Shelves on August 5
July 29, 2019
- Bayer Files Eylea for Neovascular Glaucoma
July 29, 2019
- Takeda, Meiji to End Copromotion for Rozerem
July 29, 2019
- Pfizer, Takeda Wind Up Enbrel Copromotion
July 29, 2019
- Chugai Nets 40%-Plus Profit Rise, but Keeps 3-Year EPS Target; President Nixes Avastin Biosame
July 26, 2019
- Opdivo Posts Mixed Results in 1st-Line NSCLC, Scores Win in I/O-I/O Combo
July 26, 2019
- Sumitomo Dainippon to Invest in US Blood Sample Device Startup
July 26, 2019
- EMA Accepts Xtandi for Review in Hormone-Sensitive Prostate Cancer
July 25, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…